NCT05557695Recruiting
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in the First-line Setting Through the UK Early Access Programme: Early Access Programme Outcomes In aCalabrutinib (EPIC).
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 287 (estimated)
- First submitted
- 24 Aug 2022
- Start date
- 17 Oct 2022
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Chronic lymphocytic leukaemia
- NCT number
- NCT05557695
What you commit to
- Study type: Observational
- Planned participants: 287
- From 17 Oct 2022 to the primary completion date, 1 Apr 2027
- 28 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- None listed in study protocol
Criteria the registry did not label
- The study population will include treatment-naïve patients with chronic lymphocytic lymphoma (CLL)\* who meet the following inclusion criteria:
- Treatment-naïve CLL patients who were initiated on acalabrutinib as part of the UK Early Access Programme
- Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021
- Patients aged ≥18 years old
- Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (28)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.